GlassScriptPhysician profile
Katy E Shrode
NPI 1487991568
$1,199.70
in general payments reported to CMS, 2019-2025
19 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $173 · 2023: $521 · 2024: $241 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $807 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.17 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $300.23 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $146.14 | 2023-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $136.41 | 2023-2024 | Veozah, Myrbetriq |
| Idorsia Pharmaceuticals US INC | $110.00 | 2023 | Quviviq |
| Abbvie INC. | $107.33 | 2021-2023 | |
| Pfizer INC. | $79.52 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.24 | 2021-2022 | |
| Inspire Medical Systems, INC. | $41.95 | 2024 | Inspire |
| Currax Pharmaceuticals LLC | $31.16 | 2025 | Contrave, Onzetra Xsail |
| Dynavax Technologies Corporation | $30.38 | 2025 | Heplisav-B |
| Amgen INC. | $29.56 | 2021-2023 | Repatha, Otezla |
| Intra-Sana Laboratories | $25.76 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Glaxosmithkline, LLC. | $21.21 | 2023 | Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $17.69 | 2021 | |
| Merck Sharp & Dohme LLC | $15.91 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $15.66 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $14.17 | 2024 | Auvelity |
| Genentech USA, INC. | $13.83 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katy Shrode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.